Sueta C A, Carey T S, Burnett C K
Department of Medicine, University of North Carolina, Chapel Hill 27599.
Arch Intern Med. 1989 Mar;149(3):609-12.
Several studies have shown that the majority of patients receiving digoxin can be successfully withdrawn. A medical record review was conducted to determine whether, in practice, patients were being withdrawn from digoxin. Original indications for digoxin therapy in 163 outpatients were as follows: congestive heart failure (CHF), 50%; supraventricular tachycardia (SVT), 23%; CHF and SVT, 10%; and unknown/unclear, 17%. One third of these patients were withdrawn during the 3.5-year study, and 79% remained stable, off digoxin. The most significant predictor of withdrawal was chart indication of reassessment of the need for digoxin. The majority of the patients (68%) were reassessed, and of these, almost half were withdrawn. Physicians appear to be reassessing the need for digoxin therapy, resulting in higher withdrawal rates than previously reported. Results suggest that patients with unclear original indications, a onetime indication, or without clinical evidence of CHF or SVT can be successfully withdrawn.
多项研究表明，大多数接受地高辛治疗的患者可以成功停药。进行了一项病历审查，以确定在实际情况中患者是否正在停用 地高辛。163 名门诊患者使用地高辛治疗的原始指征如下：充血性心力衰竭（CHF），50%；室上性心动过速（SVT），23%；CHF 和 SVT，10%；不明/不清楚，17%。在为期 3.5 年的研究中，这些患者中有三分之一停药，79% 停用 地高辛后病情保持稳定。停药的最显著预测因素是病历中重新评估地高辛需求的指征。大多数患者（68%）接受了重新评估，其中近一半停药。医生似乎正在重新评估地高辛治疗的必要性，导致停药率高于先前报道。结果表明，原始指征不明、一次性指征或无 CHF 或 SVT 临床证据的患者可以成功停药。
